{"organizations": [], "uuid": "0a110ea0f7c814c9d36b44148d99c6e60eb68816", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/02/14/globe-newswire-g1-therapeutics-to-report-fourth-quarter-and-full-year-2017-financial-results-on-february-21-2018.html", "country": "US", "domain_rank": 767, "title": "G1 Therapeutics to Report Fourth Quarter and Full-Year 2017 Financial Results on February 21, 2018", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.001, "site_type": "news", "published": "2018-02-14T15:00:00.000+02:00", "replies_count": 0, "uuid": "0a110ea0f7c814c9d36b44148d99c6e60eb68816"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/02/14/globe-newswire-g1-therapeutics-to-report-fourth-quarter-and-full-year-2017-financial-results-on-february-21-2018.html", "ord_in_thread": 0, "title": "G1 Therapeutics to Report Fourth Quarter and Full-Year 2017 Financial Results on February 21, 2018", "locations": [], "entities": {"persons": [], "locations": [{"name": "triangle park", "sentiment": "none"}, {"name": "n.c.", "sentiment": "none"}, {"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "g1 therapeutics, inc.", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "RESEARCH TRIANGLE PARK, N.C., Feb. 14, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq:GTHX), a clinical-stage oncology company, today announced that fourth quarter and full-year 2017 financial results will be reported on Wednesday, February 21, 2018, after the close of U.S. financial markets. The company will host a webcast and conference call at 4:30 p.m. EST to discuss the financial results and provide an update on its corporate activities and product pipeline.\nThe live call may be accessed by dialing 866-763-6020 (domestic) or 210-874-7713 (international), and entering the conference code: 9679925. A live and archived webcast of the call will be available in the Investors section of G1’s website at www.g1therapeutics.com .\nAbout G1 Therapeutics\nG1 Therapeutics, Inc., is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for the treatment of cancer. G1’s two clinical assets, trilaciclib and G1T38, are CDK4/6 inhibitors, a validated and promising class of targets for anti-cancer therapeutics. Trilaciclib and G1T38 have broad therapeutic potential in many forms of cancer and may serve as the backbone of multiple combination regimens. In addition, G1 is advancing G1T48, a potential first- / best-in-class oral selective estrogen receptor degrader, or SERD, which is targeted for the treatment of ER+ breast cancer.\nG1 is based in Research Triangle Park, N.C. For additional information, please visit www.g1therapeutics.com and follow us on Twitter @G1Therapeutics.\nForward-Looking Statements\nThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as \"may,\" \"will,\" \"expect,\" \"plan,\" \"anticipate,\" \"estimate,\" \"intend,\" and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this news release include, but are not limited to, the therapeutic potential of trilaciclib, G1T38 and G1T48, and are based on G1 Therapeutics’ expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Factors that may cause G1 Therapeutics’ actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in G1 Therapeutics’ filings with the U.S. Securities and Exchange Commission, including the \"Risk Factors\" sections contained therein and include, but are not limited to, the inherent uncertainties associated with developing new products or technologies and operating as a development-stage company; G1 Therapeutics’ ability to complete clinical trials for, obtain approvals for, and commercialize any of its product candidates; G1 Therapeutics’ ability to recruit and enroll patients in its studies; competition in the industry in which G1 Therapeutics operates; and market conditions. Except as required by law, G1 Therapeutics assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.\nContacts:\nInvestors:\nBuck Phillips\nChief Financial Officer\nSenior Vice President, Corporate Development\n919-213-9835\nRobert Uhl\nWestwicke Partners\n858-356-5932\nrobert.uhl@westwicke.com\nMedia:\nLaura Bagby\n6 Degrees Communications\n312-448-8098\nlbagby@6degreespr.com\nSource:G1 Therapeutics", "external_links": ["https://www.globenewswire.com/Tracker?data=c8GB4PHVETb2Z27_GSV_9-UUnCz9opaWdB-90nZmuKv8ZZpOsk6oRCIJCeEoxp5P9D9BSSvOrg9XsFpiinrMcve-f5FmcDYFZcHIIv2M2ZY=", "https://www.globenewswire.com/NewsRoom/AttachmentNg/018347ed-00a3-423a-aaab-4b7788f527f5", "https://www.globenewswire.com/Tracker?data=sB2GIA-gvTxZ3Bk7z3JdmMVzyjNo-aNs4DXQE8PgHXxoco3fPO6jN-0lHOJkLJFHKWgNV_Z8YFYddCm0qk0b-WYEgbpnGYskXbowNXkHPQk=", "https://www.globenewswire.com/Tracker?data=c8GB4PHVETb2Z27_GSV_9-UUnCz9opaWdB-90nZmuKu6E9JQfYiAJJxMk75OG1m7QjBdYh1jI6oXGBRqkLWutJEzDxWwguRdDCjGpDA8LOk=", "https://www.globenewswire.com/Tracker?data=FnDM_7aQ_mZVJ4f7wiu-_YKmxZPgM2URLOfYzKFBSumKls5YBzRyuK-o-8k5tORNzKne-vCitFgbkdL3fGDWfew_tJ8TzWNN5HCHMhcFz-w="], "published": "2018-02-14T15:00:00.000+02:00", "crawled": "2018-02-14T15:14:00.005+02:00", "highlightTitle": ""}